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Abstract
Background: Gene identification using linkage, association, or genome-wide expression is often
underpowered. We propose that formal combination of information from multiple gene-
identification approaches may lead to the identification of novel loci that are missed when only one
form of information is available.
Methods: Firstly, we analyze the Genetic Analysis Workshop 16 Framingham Heart Study
Problem 2 genome-wide association data for HDL-cholesterol using a “gene-centric” approach.
Then we formally combine the association test results with genome-wide transcriptional profiling
data for high-density lipoprotein cholesterol (HDL-C), from the San Antonio Family Heart Study,
using a Z-transform test (Stouffer’sm e t h o d ) .
Results: We identified 39 genes by the joint test at a conservative 1% false-discovery rate,
including 9 from the significant gene-based association test and 23 whose expression was
significantly correlated with HDL-C. Seven genes identified as significant in the joint test were not
independently identified by either the association or expression tests.
Conclusion: This combined approach has increased power and leads to the direct nomination of
novel candidate genes likely to be involved in the determination of HDL-C levels. Such information
can then be used as justification for a more exhaustive search for functional sequence variation
within the nominated genes. We anticipate that this type of analysis will improve our speed of
identification of regulatory genes causally involved in disease risk.
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The ultimate goal of genetic studies of complex diseases
is the identification of the genes that are causally
involved in risk. Genome-wide association studies
(GWAS) (like their predecessors, linkage studies)
attempt to identify genomic regions that are likely to
harbor functional sequence variants influencing disease
risk. For linkage studies, the size of the putative target
region is on the order of 10 Mb while GWAS generally
identify much smaller genomic regions of 500 kb to
1 Mb. Once such a region is found, the critical goal must
then be to identify the causal gene(s) involved and their
functional variants. In this paper, we propose an
approach that leads to the direct nomination of
empirically chosen positional candidate genes using
independent transcriptional and genetic information.
Once nominated, such candidate genes should be
examined exhaustively to determine their causal status.
In a “successful” genome-wide association study, the
result is localization of a genomic region; actual
identification of causally involved genes requires sub-
stantially more information. Therefore, joint utilization
of multiple sources of independent information (such as
transcriptional profiling) is ultimately required to
enhance inference about causal relationships. Because
genes (or other contiguous genomics regions) remain the
primary functional units of the human genome, we focus
on gene-based tests of genetic, transcriptional, or
proteomic data to determine whether a given gene is
likely to be involved in the determination of a complex
disease-related phenotype. This gene-centric approach
allows replication studies to be focused on genes rather
than variants. This analysis approach for GWAS data has
been suggested as best practice [1], however it has yet to
receive broad implementation.
Gene expression measurements reflect quantitative var-
iation in transcript-specific mRNA levels and thus
represent phenotypes lying very close to the direct action
of genes. By globally searching for gene transcripts
having levels that correlate with more classical measures
of disease related phenotypes, it should be possible to
nominate or prioritize novel candidate genes for more
extensive genetic analysis. Combining such transcrip-
tional information with the results of GWAS should
provide a powerful approach for the selection of disease-
related genes.
Methods
As an example of our gene-centric approach, we focus on
the dissection of genetic determinants influencing high-
density lipoprotein cholesterol (HDL-C) levels, an
important endophenotype inversely related to risk of
cardiovascular disease. Age, sex, and their interactions as
well as smoking status were included as covariates in all
analyses.
Framingham Heart Study data
For the genetic component of our tests, we utilized the
genome-wide association information available in the
Genetic Analysis Workshop 16 Problem 2 single-nucleo-
tide polymorphism (SNP) data obtained from the long-
running Framingham Heart Study (FHS) [2]. The full
FHS pedigree was trimmed using PEDSYS [3] to include
only genotyped individuals (n = 6852) plus the minimal
set of untyped individuals required to maintain familial
relationships. The trimmed pedigree consists of 12,789
subjects in 1059 extended families.
Genotyping was performed by Affymetrix for approxi-
mately 550,000 SNPs. The genotypes were cleaned for
mendelian errors using an automated procedure in
which a mistyping analysis is conducted with the
computer program SimWalk2 [4,5] and those genotypes
for which the probability of being mistyped exceeds a
certain threshold are blanked. Genotypes were then
coded as the number of copies of the minor allele.
Missing genotypes were imputed (for genotyped indivi-
duals only) using the computer program Merlin [6,7].
For each cohort fasting HDL-C data were taken from the
first visit for which they were available. HDL-C measures
were blanked for individuals using cholesterol-lowering
drugs.
Gene-centric test of association
To quantify the evidence for a given gene influencing
HDL-C levels we employed an omnibus gene-based test
of association. We defined the physical location of each
gene (extended by 25 kb in either direction) and then
selected the Problem 2 SNPs within each region. We
calculated the effective number of SNPs within a gene
region using the method of Li and Ji [8] as implemented
in SOLAR [9]. We then performed a marginal measured
genotype analysis on each SNP using SOLAR and
calculated an adjusted p-value for the best marginal
SNP. The measured-genotype analysis [7] was conducted
for each polymorphic SNP: the number of minor alleles
is added to the polygenic model as a covariate in order
to assess the effect of the SNP genotype on the trait
mean. This model was fitted to the data and compared,
using a likelihood ratio test, to the null model. Two
times the difference in the log likelihoods of these
models was distributed as a chi-square random variable
with one degree of freedom. The likelihood ratio test
statistic was recorded for each tested SNP. We adjusted
the p-values against the effective number of SNPs using
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effective,w h e r ecorrected is the
corrected p-value, nominal is the uncorrected p-value, and
effective is the effective number of SNPs. Our approach
explicitly allows for non-independence among family
members and the effects of other potential covariates.
A given SNP may fall into the focal bin of more than one
gene/transcript. This has the potential of inducing some
positive correlation among test statistics for nearby
genes. However, our reliance on the false-discovery rate
(FDR) approach, with its known robustness in the
presence of such positive non-independence, amelio-
rates this potential problem [10].
Genome-wide transcriptional profiles
T h ee x p r e s s i o na n a l y s i sw a sc o n d u c t e da sp a r to ft h eS a n
Antonio Family Heart Study, initiated in 1992 to
investigate the genetics of cardiovascular disease and its
risk factors in Mexican Americans [11]. The expression
profiling methodology is described, in detail, in Göring
et al. [12]. All protocols were approved by the Institu-
tional Review Board of the University of Texas Health
Science Center at San Antonio. We used publically
available information from our previously published
large-scale transcriptional profiling study of lymphocyte
samples from 1240 Mexican Americans [12] in which we
had quantified the evidence for phenotypic correlation
between HDL-C levels and gene expression levels. In this
data set a c
2 ’tail’ test was to assess whether there was a
significant excess of samples with transcript-specific
expression values above the 95
th percentile of the null
distribution based on manufacturer-provided negative
control samples. This allowed the detection of even
those RNA molecules that are clearly present above
baseline levels in some individuals. We identified a total
of 22,413 transcripts with significantly detectable expres-
sion levels [12]. Using a conservative FDR of 1%, we
identify 102 transcripts that were significantly correlated
with HDL-C levels.
Joint test
We then simultaneously utilized our transcriptional and
genetic information by the application of a joint gene-
based test that takes into account the evidence for a
phenotypic relationship between HDL-C levels and a
gene’s expression and the strength of the association
between SNPs in (or near) the gene with HDL-C levels.
We combine these two tests using a Z-transform test also
known as ‘Stouffer’sm e t h o d ” [13]. The method basically
converts p-values to Z-scores using an inverse normal
transformation. The Z-scores are summed and then
scaled by the square root of the number of combined
tests. The resulting test statistic is distributed as a
standard normal variate that is then transformed back
to a combined overall p-value. This omnibus test is not
dependent upon the distribution of the data but depends
only upon the expected uniform distribution of p-values
under the null hypothesis.
Results and discussion
For each cohort, the first HDL-C measure was included
in the phenotype file, along with age at exam and
smoking status. HDL-C measures were blanked for
individuals using cholesterol-lowering drugs. In total
there were 6334 individuals with both HDL-C measures
and genotype data, with HDL-C measures ranging from
16 to 206 (mean 53.6 ± 0.2). Within our analysis dataset,
age at exam ranged from 5 to 72 (mean 38.3 ± 0.1).
There were 6301 individuals with data on both HDL-C
and age and 6152 individuals with both HDL-C and
smoking status.
The genes considered in this investigation were those
corresponding to the 22,413 transcripts identified in the
expression profiling. Of these, there were 17,350 gene
regions with a least one effective SNP located within a
25-kb extension of either side of the physical gene
location (NCBI build 36.3). SNP counts ranged from
1 to 597, with an average of 21 ± 1 SNPs per gene region.
The 25-kb extension of the boundaries was selected to
maximize the number of SNPs that may influence the
target gene while minimizing the number of over-
lapping; this parameter is investigator-driven and can
be adjusted as required.
Of the 17,350 gene regions tested, 14 were significantly
associated with HDL-C from the measured genotype
analysis, following correction of the p-value for the
effective number of SNPs within the region, at a 1% FDR.
These results are shown in Table 1.
In the joint test there were a total of 39 genes significant
at a highly conservative 1% FDR, including 9 from the
significant measured genotype set and 23 with expres-
sion that was significantly correlated with HDL-C. Seven
genes identified as significant in the joint test were not
identified by either the association or expression tests
independently (ABCG1, C12orf62, C6orf64, GPBAR1,
LOC283551, LYRM1,a n dPRPF38A). The results of the
joint test are shown in Additional File 1.
The genes shown in Table 2 are prime candidates for
resequencing and variant typing, empirically selected
based on evidence both from transcriptional profiling
and genome-wide association. One of the most signifi-
cant genes is CETP (cholesteryl ester transfer protein), a
well known cholesterol binding gene. In total, there are
seven well known lipid metabolism genes prioritized by
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IL1R2,a n dLPL). Interestingly, the list also prioritizes a
number of genes of little-known function, such as
NLRC5 (NLR family CARD domain containing 5),
TCTN1 (tectonic family member 1), and TPPP3 (tubulin
polymerization-promoting protein family member 3),
which would not be selected by any form of candidate
gene approach.
It can also be seen that there are situations in which genes
show a highly significant correlation between their expres-
sion and HDL-C, but no evidence of association at the
physical location of the gene, such as IL1R2 (Table 2).
Similarly, there are cases (SMURF1) where the association
information drives the combined tests. We have retained all
genes that exhibit combined significance. An individual
reader may choose to further focus on only those genes that
exhibit at least nominal significance on each dimension.
While this approach shows great potential for speeding
gene identification, it also has several limitations. One
potential weakness is the focus on regulatory variation.
While there is a growing belief that much of quantitative
phenotypic variation may stem from regulatory varia-
tion, other types of mechanisms (e.g., structural varia-
tion that alters protein-protein interactions) can also be
involved. Similarly, genes whose expression is not
detected in the target tissue may be missed. Thus, as
with all discovery-based approaches, only positive
findings admit interpretation. A gene cannot be ruled
out using these methods.
This paper combines information from two different
population studies. Both samples, however, are ascer-
tained without regard to phenotype. It is possible that
the relationship between expression levels and disease-
related phenotypes may vary across populations. How-
ever, we would expect this to diminish signal rather than
yield false positives. Optimally, expression and associa-
tion results would come from the same data set.
Conclusion
Our results suggest that the formal combination of
information from orthogonal sources may lead to the
identification of novel loci that are missed when only
one form of information is available. For the current
study, we have combined existing information on the
correlation of gene expression levels with HDL-C and
the association between SNPs near these genes with
HDL-C levels. Our simple measure of evidence is
effectively a measure of significance resulting from the
combination of p-values from two separate tests, both
of which are tests of a gene-centric hypothesis. Of
course, this approach can be made substantially more
powerful when both forms of information are available
in a single study and a formal, true joint test is
specified. In the current application, our results empiri-
cally nominate genes that are likely to be directly
involved in quantitative HDL-C variation. Many of
these genes would not have been identified using a
classical pathways-based combinatorial approach
because their functions have yet to be identified.
Many would also not have been identified by using
each approach in isolation. A logical next step would be
either replication or, given the magnitude of current
evidence, a direct move to resequencing to identify
functional variants.
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Study; GAW16: Genetic Analysis Workshop 16; GWAS:
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Table 1: The 14 measured genotypes results for HDL-C significant at a 1% FDR
Gene Chromosome Best SNP c
2 Uncorrected p-value Corrected p-value Number of SNPs Effective SNPs
CETP 16 rs3764261 159.09 <1.0 × 10
-20 <1.0 × 10
-20 25 20
HRNBP3 17 rs898533 1621.74 <1.0 × 10
-20 <1.0 × 10
-20 41 36
SMURF1 7 rs9297145 1599.57 <1.0 × 10
-20 <1.0 × 10
-20 20 12
KLHL6 3 rs12496193 1594.56 <1.0 × 10
-20 <1.0 × 10
-20 32 20
NLRC5 16 rs11508026 121.65 <1.0 × 10
-20 <1.0 × 10
-20 40 31
LPL 8 rs17410962 52.95 3.4 × 10
-13 4.5 × 10
-12 20 13
IQCG 3 rs11547008 46.68 8.4 × 10
-12 5.9 × 10
-11 12 7
ZNF613 19 rs4987042 42.82 6.0 × 10
-11 4.8 × 10
-10 13 8
RCAN2 6 rs1442219 33.60 6.8 × 10
-9 8.1 × 10
-8 26 12
CYP51A1 7 rs2229188 29.60 5.3 × 10
-8 2.1 × 10
-7 94
IL8 4 rs2886920 27.90 1.3 × 10
-7 1.5 × 10
-6 18 12
PACRG 6 rs13202088 27.56 1.5 × 10
-7 1.0 × 10
-5 127 69
CC2D2A 4 rs16892095 25.32 4.9 × 10
-7 1.1 × 10
-5 44 23
LYRM2 6 rs4707557 23.98 9.7 × 10
-7 9.7 × 10
-6 13 10
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